NCT02537015 - An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2015

Primary Completion Date

August 11, 2016

Study Completion Date

August 11, 2016

Conditions

Primary Open-Angle GlaucomaOcular Hypertension

Interventions

DRUG

Bimatoprost

Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.

Trial Locations (9)

27262

Cornerstone Health Care; Cornerstone Eye Care, High Point

28204

Mundorf Eye Center, Charlotte

30260

Clayton Eye Center, Morrow

37803

University Eye Specialists, Maryville

38119

Total Eye Care, Memphis

72704

Vold Vision, Fayetteville

78229

R&R Eye Research, LLC, San Antonio

90701

Sall Medical Research Center, Artesia

92663

Eye Research Foundation, Newport Beach

All Listed Sponsors

lead

ForSight Vision5, Inc.

INDUSTRY